Petra Smajić

Petra Smajić

Auto-generated profile, based on publicly available information

Petra Smajić

Clinic for Infectious Diseases, University Hospital Centre Osijek, 4 Josip Huttler Street, HR-31000 Osijek, Croatia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BGBarbara Grubisic
Barbara Grubisic
LŠLuka Švitek
Luka Švitek
MZMihaela Zlosa
Mihaela Zlosa
PSPetra Smajić
Petra Smajić
DMDavid Matić
David Matić
IBInes Bilić-Čurčić
Ines Bilić-Čurčić
Acute hyperglycaemia is a common COVID-19 complication linked to adverse outcomes. The combined prognostic value of cytokine activation and acute insulin resistance in non-diabetic patients remains unclear. In this prospective cohort study, we enrolled 144 hospitalised adults with RT-PCR-confirmed SARS-CoV-2 infection and no prior diabetes. We aimed to characterise metabolic–inflammatory phenotypes and evaluate their association with disease severity and post-discharge glycaemic outcomes. Patients were classified as normoglycaemic or dysglycaemic based on repeated glucose profiles. Dysglycaemic patients were further phenotyped as stress hyperglycaemia (SHG) or newly diagnosed diabetes (NOD). This classification was based on post-discharge glycaemic assessment at 3 and 6 months, distinguishing transient from persistent hyperglycaemia. Admission hyperglycaemia was associated with a consistently elevated pro-inflammatory cytokine pattern. However, cytokine concentrations were comparable between stress hyperglycaemia and newly diagnosed diabetes, indicating that inflammatory burden alone does not explain metabolic persistence. In contrast, insulin resistance (HOMA-IR) was markedly higher in the newly diagnosed diabetes phenotype. Along with admission oxygenation and key cytokine signals, this contributed to risk stratification for severe disease. In conclusion, early admission assessment of glucose and insulin resistance identifies high-risk metabolic phenotypes. This enables targeted in-hospital risk stratification and post-discharge glycaemic surveillance.

9 September 2025 in Acta Microbiologica Hellenica
Verified
Journal Article
Open access
PDF file
NVNika Vlahović Vlašić
Nika Vlahović Vlašić
LZLada Zibar
Lada Zibar
PSPetra Smajić
Petra Smajić
LŠLuka Švitek
Luka Švitek
Domagoj DrenjančevićDomagoj Drenjančević
Domagoj Drenjančević
Background: Pancreatic stone protein (PSP) has emerged as a promising biomarker for the early diagnosis of sepsis, infectious diseases, and chronic inflammatory conditions, including cancer, diabetes, and inflammatory bowel disease. This review evaluates the role of PSP as a biomarker and functional protein, emphasizing its diagnostic and prognostic value. Methods: This review was conducted through a comprehensive literature search using the PubMed database, covering publications from the discovery of PSP in the 1980s up to 2025. The information was gathered into thematic sections to provide a comprehensive and structured review of PSP as a biomarker and functional protein in health and disease. Results: A total of 256 articles were reviewed and critically assessed, with 80 meeting the inclusion criteria and forming the basis of this review. The reviewed literature underscores PSP as a multifaceted protein involved in inflammation, immune modulation, tissue regeneration, and systemic infection. PSP shows promise as an early biomarker in critically ill patients. Conclusions: PSP is a clinically promising but not yet fully validated biomarker. To enable its routine clinical application, standardized diagnostic cutoffs, validation through multicenter trials, and integration with existing biomarker panels are required. Further research is warranted to fully establish its diagnostic and prognostic potential across diverse clinical settings.

27 April 2020 in Southeastern European medical journal
Verified
Journal Article
Open access
PDF file
PSPetra Smajić
Petra Smajić
ESEma Schönberger
Ema Schönberger
VPVlatka Periša
Vlatka Periša
JPJasminka Sinčić Petričević
Jasminka Sinčić Petričević
LZLada Zibar
Lada Zibar
KKKristina Kralik
Kristina Kralik
Aim: Multiple myeloma (MM) patients might require haemodialysis (HD) and/or plasma exchange (PE) in cases of acute kidney injury (AKI) and/or chronic kidney disease (CKD) and/or other indications. The study analysed the survival of MM patients who required HD and/or PE. Subjects and methods: All 144 patients treated for MM at the University Hospital Centre Osijek between 1994 and 2018 (of whom 47.9 % were men) were included in the study. Data were collected from medical records. MedCalc Statistical Software version 17.8.2 was used for the statistical analysis, with significance set at α = 0.05. Results: Forty-three of 144 MM patients (29.9 %) were treated with HD and/or PE. Male patients required HD or PE more often than female patients (62.8 % vs 37.2 %, P = 0.02). Patients who did not require HD or PE were significantly older at the time of their death than the patients treated with HD or PE [75 (interquartile range, IQR, 72 – 77) vs 72 (IQR 66 – 75) years; P = 0.009, Mann-Whitney test]. Among all patients who required acute or chronic HD, PE or a combination of the treatments, the longest life span was found in 17 patients who were treated with chronic HD (median 12 months, IQR 8 – 58). Conclusion: Kidney failure requiring HD or PE in MM was associated with a significantly shorter life span in comparison with other MM patients. Chronic HD patients had the longest survival among patients who required acute or chronic HD, PE or a combination of the treatments. In general, MM patients in need for HD and/or PE had poor survival.

18 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MZMihaela Zlosa
Mihaela Zlosa
LŠLuka Švitek
Luka Švitek
BGBarbara Grubisic
Barbara Grubisic
NVNika Vlahović Vlašić
Nika Vlahović Vlašić
PSPetra Smajić
Petra Smajić
TKTomislav Kizivat
Tomislav Kizivat
Background: COVID-19 is a multisystem disorder associated with inflammatory, metabolic, electrolyte, and endocrine disturbances. However, the clinical relevance of dysnatremia and acute hormonal alterations remains uncertain, particularly when assessed alongside established clinical risk factors. Methods: This prospective cohort study included 252 adults hospitalized with confirmed COVID-19. Clinical, laboratory, hormonal, and metabolic parameters were assessed at admission, and their associations with disease severity, intensive care unit (ICU) admission, and in-hospital mortality were analyzed. Results: The median age was 73 years, 50.4% of patients were female, and severe or critical disease was present in 81.7%. Dysnatremia and/or endocrine alterations were detected in 55.2% of patients, including hyponatremia in 16.7%, while thyroid-function alterations were observed in 40.9%. Dysnatremia was associated with higher glucose levels and inflammatory-cell changes. Several hormonal and metabolic parameters showed statistically significant univariate associations with adverse outcomes; however, their discriminative performance was weak, with AUC values below clinically meaningful thresholds. After adjustment for major clinical confounders, dysnatremia and endocrine alterations were not independent predictors of disease severity, ICU admission, or mortality. Conclusions: These findings suggest that electrolyte and endocrine abnormalities in hospitalized COVID-19 patients primarily reflect systemic stress physiology and acute disease burden rather than functioning as independent prognostic biomarkers.